News & events
Stay up to date with the latest news and developments
The agreement aims to establish a long-term partnership between Iconovo and Lonza in spray-dried formulations.
Iconovo’s CEO Anders Månsson, was recently interviewed by DNB Carnegie to discuss the company’s latest quarterly report.
Iconovo’s new Interim CEO, Anders Månsson, made his first official appearance for the company when he presented Iconovo at DNB Carnegie’s Småbolagsdag on 27 November.
The Board of Directors of Iconovo AB (“Iconovo” or the “Company”) has today resolved on a directed share issue of approximately SEK 25 million (the “Directed Issue”), and on an issue of shares of approximately SEK 24.6 million with preferential rights for the Company’s existing shareholders (the “Rights Issue”, together the “Issues”).
Iconovo AB (publ), a leader in the development of inhalable drugs based on proprietary inhalers and dry powder formulations, has today appointed Anders Månsson as interim CEO of Iconovo AB. The Board of Directors has in parallel initiated a process to recruit a permanent CEO, for which Anders also is a candidate.
Upcoming events
BUSINESS MEETINGS AND EVENTS
NLS Days
Sept 8-9, Stockholm, Sweden
IPAC RS
Sept 16-17, New Jersey, USA
CPHI
Oct 6-8, Milan, Italy
World Vaccine Congress
Oct 19-20, Amsterdam, The Netherlands
MVIC Symposium
Oct 21-22, Lund, Sweden
BIO Europe
Nov 9-11, Cologne, Germany
DDL
Dec 9-11, Edinburgh, Scotland